Tenaya Therapeutics (TNYA) News Today $0.77 -0.02 (-2.22%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.79 +0.02 (+2.52%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Analysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX) and Tenaya Therapeutics (TNYA)May 20, 2026 | theglobeandmail.comPositive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with ...May 15, 2026 | markets.businessinsider.comTenaya Therapeutics' gene therapy data highlights early heart rhythm improvementsMay 15, 2026 | msn.comTenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC TranscriptMay 15, 2026 | seekingalpha.comTenaya Therapeutics Reports Significant Reductions in Premature Ventricular Contractions in Interim Results from TN-401 Gene Therapy Clinical TrialMay 15, 2026 | quiverquant.comQPositive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVCMay 15, 2026 | globenewswire.comTenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?May 12, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)May 11, 2026 | theglobeandmail.comTenaya Therapeutics (NASDAQ:TNYA) Upgraded by Wall Street Zen to "Hold" RatingMay 9, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Tenaya Therapeutics (TNYA)May 7, 2026 | theglobeandmail.comTenaya Therapeutics (NASDAQ:TNYA) Posts Earnings Results, Hits EstimatesMay 6, 2026 | marketbeat.comTenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comTenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on WednesdayMay 6, 2026 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 3, 2026 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 4.4% - Here's WhyApril 30, 2026 | marketbeat.comTenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2 ...April 27, 2026 | finance.yahoo.comTenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026April 27, 2026 | globenewswire.comTenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20March 27, 2026 | msn.comWilliam Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product PipelineMarch 24, 2026 | insidermonkey.comTenaya Therapeutics, Inc. (TNYA) reports Q4 EPS of (12c), in line with consensusMarch 20, 2026 | msn.comTenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam DealMarch 13, 2026 | finance.yahoo.comTenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 11, 2026 | globenewswire.comTenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular DystrophyMarch 9, 2026 | finance.yahoo.comTenaya Therapeutics Reports TN-301 Outperforms Givinostat in Enhancing Muscle Function and Addressing DMD CardiomyopathyMarch 9, 2026 | quiverquant.comQTenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular DystrophyMarch 9, 2026 | globenewswire.comTenaya Therapeutics Announces Major Cardiovascular Gene Target CollaborationMarch 8, 2026 | theglobeandmail.comAlnylam’s research pact worth up to $1.1B sends Tenaya higherMarch 5, 2026 | seekingalpha.comTenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatmentsMarch 5, 2026 | reuters.comTenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease TherapeuticsMarch 5, 2026 | globenewswire.comTenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026March 2, 2026 | globenewswire.comTenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Group Gp Lp Column III Sells 658,440 SharesFebruary 27, 2026 | insidertrades.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Moderate Buy" from AnalystsFebruary 17, 2026 | marketbeat.comAssessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash RunwayJanuary 24, 2026 | finance.yahoo.comHow Does Tenaya Therapeutics' (TNYA) Extended Cash Runway Reframe Its Cardiac Gene Therapy Ambitions?January 21, 2026 | finance.yahoo.comMorgan Stanley backs Tenaya Therapeutics (TNYA) as SMID-cap biotech primed to outperform in 2026January 19, 2026 | msn.comMorgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotechJanuary 12, 2026 | msn.comMorgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap BiotechJanuary 12, 2026 | insidermonkey.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated MilestonesJanuary 9, 2026 | finanznachrichten.deTenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated MilestonesJanuary 9, 2026 | globenewswire.comTenaya Therapeutics announces orderly board leadership transitionJanuary 3, 2026 | msn.comTenaya Therapeutics price target lowered to $4 from $6 at CanaccordDecember 18, 2025 | msn.comTenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's ChangedDecember 14, 2025 | finance.yahoo.comTenaya Therapeutics announces interim data from cohort one of RIDGE-1 trialDecember 11, 2025 | msn.comTenaya Therapeutics Announces Pricing of Public OfferingDecember 11, 2025 | globenewswire.comTenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks TranscriptDecember 11, 2025 | seekingalpha.comTenaya Therapeutics stock falls on proposed share and warrant offeringDecember 11, 2025 | uk.investing.comTenaya Therapeutics Announces Proposed Public OfferingDecember 11, 2025 | globenewswire.comTenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene TherapyDecember 11, 2025 | globenewswire.comTenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVCDecember 11, 2025 | globenewswire.comTenaya Therapeutics: Risky But Promising Cardiac Gene PlatformDecember 5, 2025 | seekingalpha.com Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNYA Media Mentions By Week TNYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNYA News Sentiment▼-0.600.45▲Average Medical News Sentiment TNYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNYA Articles This Week▼43▲TNYA Articles Average Week Get the Latest News and Ratings for TNYA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Tenaya Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Amphastar Pharmaceuticals News Today ARS Pharmaceuticals News Today Relmada Therapeutics News Today Solid Biosciences News Today CryoPort News Today Zevra Therapeutics News Today Sutro Biopharma News Today Candel Therapeutics News Today EIKN News Today Gyre Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNYA) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredJune 12: Elon Musk’s “Day-One Retirement Plan.”SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredJune 4: The day smart money moves (not June 12)Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morga...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
